世界肺癌大会（WCLC）是由国际肺癌研究协会（IASLC）主办的专注于肺癌的顶级国际学术会议，每年举办一次，旨在为全球肺癌领域的学者、专家、从业人员提供最新临床研究、科学研究成果及广阔的学术交流平台。今年WCLC会议仍然覆盖基础研究、转化研究和临床研究等医学研究领域，涉及早中期、局部晚期或转移性非小细胞肺癌、小细胞肺癌、恶性胸膜间皮瘤等胸部恶性肿瘤的筛查与诊断，及各类创新疗法的最新临床研究与科研成果。
2024 WCLC大会将于美国当地时间9月7-10日在圣地亚哥举行。美国当地时间7月23日WCLC官网已披露口头报告（18个Oral专场）、迷你口头报告（19个Mini Oral专场）部分摘要标题。【肿瘤资讯】梳理已披露标题Oral专场重磅研究，以飨读者。
OA01. Perioperative Strategies 1
OA01.03
Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
讲者 David Jones
OA01.04
A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer
讲者 Xiaoliang Zhao
OA02. Redefining First-Line EGFR Therapy
OA02.03
A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
讲者Anwen Xiong
OA02.04
Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
讲者 Se-Hoon Lee
OA03. Predicting the Future: Novel Pathology Assessments and Imaging Biomarkers
OA03.03
Predicting Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced NSCLC with Machine Learning and CT Radiomics
讲者 Calum MacAulay
OA03.04
Deep Muitiple Instance Learning-Enabled Gene Mutation Prediction of Lung Cancer from Histopathology Images
讲者 Shan Xiong, MD
OA03.05
Deciphering Single-Cell Resolved Tumour Microenvironment Profiles Using Spatial Metabolic Mapping
讲者 Kenneth O'Byrne
OA04. Antibody Drug Conjugates in SCLC
OA04.03
Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01
讲者 Charles Rudin
OA04.04
Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
讲者 Afshin Dowlati
OA04.05
SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), In Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC)
讲者 Jie Wang
OA05. Local Consolidative Therapy for Metastatic NSCLC
OA05.03
Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial
讲者 Shuo Yang
OA05.04
Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study
讲者 Lauren Brown
OA05.05
Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer
讲者 Rui Fu
OA05.06
Radiotherapy Combined with Enhanced Immunotherapy for NSCLC
讲者 Chuanwang Miao
OA06. Novel Immunotherapy Strategies and Combinations
OA06.03
SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1
讲者 Yi-Long Wu
OA06.04
Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
讲者 Melina Marmarelis
OA06.05
IL15 Superagonist (N-803, Anktiva) + Checkpoint Inhibitor (CPI) Prolongs OS in 2ndline or Greater NSCLC Patients Failing CPI
讲者 John Wrangle
OA07. Opportunities for Optimizing Supportive Care
OA07.03
The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients
讲者 Yuan Yuan
OA07.04
Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care
讲者 Shalini Vinod
OA07.05
Improving Supportive and Social Care in Lung Cancer with the 4R Oncology Model for Patient Care Planning and Delivery
讲者 Mary Pasquinelli
OA07.05
Phase 3 Study of HR20013 For Prevention of Cisplatin-based Chemotherapy-induced Nausea and Vomiting (PROFIT Study)
讲者 Li Zhang
OA08. The New Generation of Cytotoxics
OA08.03
Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial
讲者 Trevor Feinstein
OA08.04
Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial
讲者 Benjamin Besse
OA08.05
Sacituzumab Govitecan vs Docetaxel in Patients with Mnsclc Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01
讲者 Marina Garassino
OA08.06
Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study
讲者 Jhanelle Gray
OA10. DLL3 Targeting BiTE Therapies in SCLC
OA10.03
Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
讲者 Jacob Sands
OA10.04
Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC
讲者 Martin Wermke
OA10.05
Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer
讲者 Noura Choudhury
OA11. Shifting the Bar in the Front Line Immunotherapy Setting
OA11.03
Results of a Phase III Trial of Prolgolimab with Chemotherapy as First-Line Therapy for Patients with Advanced Non-Squamous NSCLC: DOMAJOR
讲者 Daniil Stroyakovsky
OA12. Adding EGFR and Radiation to Peri-operative Approaches
OA12.03
APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
讲者 Mariano Provencio
OA13. Perioperative Strategies 2
OA13.03
ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
讲者 Hidehito Horinouchi
OA13.04
I-SABR-SELECT: A Radiomics-Based Model for Personalized Immunotherapy for Early-Stage Non-Small Cell Lung Cancer
讲者 Joe Chang
OA14. New Horizons in Targeting KRAS G12C
OA14.03
KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
讲者 Qing Zhou
OA14.04
Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC
讲者 Adrian Sacher
OA15. Profiling the Tumour Microenvironment of Lung Cancer Metastasis
OA15.03
Clinicogenomic Landscape of Lymph Node Metastases in TRACERx
讲者 Takahiro Karasaki
OA15.04
Multi-Omic Profiling of Paired Non-Small Cell Lung Cancer and Draining Lymph Nodes Reveals Novel T-Cell Differentiation Patterns
讲者 Vivian Gerretsen
OA15.05
Single-Cell Spatial Architectures of Paratumor Zone Determines the Prognosis of Multiple Lung Cancers
讲者 Xiaoqiu Yuan
OA15.06
Spatiotemporal Genomic and Transcriptomic Analysis Reveal Molecular Landscape and Intratumoral Heterogeneity in Non-Smoking Lung Cancer
讲者 Wenxiang Wang
OA16. Transforming Cancer Therapy: Biomarkers and Novel ADCs
OA16.03
Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY
讲者 Hidehito Horinouchi
OA16.04
Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-Averexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
讲者 James CH Yang
OA16.05
Preliminary Results from a FIH Study of GQ1005, A Novel HER2-ADC, in Patients with Advanced HER2-Expressing Solid Tumors and HER2-Mutated NSCLC
讲者 Wei Li
OA17. Increasing Access to Early Lung Cancer Detection
OA17.03
Missed Opportunities for Early Lung Cancer Detection in a Multi-Disciplinary Thoracic Oncology Clinic Cohort
讲者 Raymond Osarogiagbon
OA17.04
Implementation of a Natural Language Processing (NLP) Model to Detect Incidental Lung Nodules in a Nationwide Health Care Network
讲者 Clarissa Baldotto
OA17.05
A Randomized Controlled Trial of a Digital Lung Health Intervention to Facilitate Smoking Cessation and Lung Cancer Screening
讲者 Mary Cooley
OA17.06
Impact of Using Smoking Duration in Place of Pack-Years as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities
讲者 Chloe Su
OA18. Pleural, Mediastinal and Undifferentiated Thoracic Cancers
OA18.03
Real-World Data on the Efficacy and Safety of Lenvatinib in Patients with Previously Treated Thymic Carcinoma
讲者 Nobuaki Mamesaya
OA18.04
Pembrolizumab Plus Lenvatinib in Second-Line Pleural Mesothelioma Patients: A Single Arm Phase II Study (PEMMELA Cohort 2)
讲者 Li-Anne Douma
OA18.05
Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
讲者 Yaoyao Zhu
OA18.06
Characteristics and Outcomes of Patients with SMARCA4-Deficient Undifferentiated Thoracic Tumors
讲者 Alissa Cooper
排版编辑：肿瘤资讯-Yuno
苏公网安备 32059002004080号
